Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

BACKGROUND: Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin’s lymphoma. Bortezomib is the first product to be approved for the treatment of patients with previously untreated MCL, for whom haematopoietic stem cell transplantation is unsuitable, and is used in combination with...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Autores principales: van Keep, Marjolijn, Gairy, Kerry, Seshagiri, Divyagiri, Thilakarathne, Pushpike, Lee, Dawn
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4972997/
https://ncbi.nlm.nih.gov/pubmed/27488675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2633-2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares